Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries

Johan Wikström, Martin N. Wasser, Peter M T Pattynama, Lorenzo Bonomo, Bernd Hamm, Alessandro Del Maschio, Michael V. Knopp, Guy Marchal, Jelle O. Barentsz, Matthijs Oudkerk, Hans Rainer Hentrich, Massimo Daprà, Miles A. Kirchin, Ningyan Shen, Alberto Spinazzi, Håkan Ahlström

Research output: Contribution to journalArticle

Abstract

Rationale and Objectives: To evaluate 4 doses of gadobenate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (CE-MRA) of the pelvic arteries and to compare CE-MRA with unenhanced time-of-flight MRA (2D-TOF-MRA). Methods: A multicenter Phase II dose-finding study was performed in 136 patients with Gd-BOPTA doses of 0.025, 0.05, 0.1, and 0.2 mmuol/kg bodyweight. Evaluation of CE-MRA images and comparison with 2D-TOF-MRA images was performed onsite and by 2 blinded offsite reviewers in terms of subjective image quality, number of lesions detected, and confidence in lesion characterization. Results: Significant (P <0.05) improvements over unenhanced findings were observed for CE-MRA at all dose levels. For reviewer I and the onsite investigators, the overall image quality increased up to a dose of 0.1 mmol/kg and then plateaued. For reviewer 2, increased image quality was noted up to a dose of 0.2 mmol/kg. Significant (P <0.005) increases in diagnostic confidence on CE-MRA versus unenhanced MRA was observed for all dose groups by reviewer 1 and the onsite investigators and for the 0.1 and 0.2 mmol/kg dose groups by reviewer 2. No serious adverse events were recorded that were attributable to the study drug and no trends in laboratory parameters, vital signs, or electrocardiogram recordings were observed. Conclusions: Gadobenate dimeglumine-enhanced MRA is safe and significantly more effective than unenhanced 2D-TOF-MRA for imaging the pelvic arteries. A dose of 0.1 mmol/kg appears the most appropriate dose for subsequent Phase III clinical evaluation.

Original languageEnglish
Pages (from-to)504-515
Number of pages12
JournalInvestigative Radiology
Volume38
Issue number8
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Magnetic Resonance Angiography
Arteries
Research Personnel
Vital Signs
Electrocardiography
gadobenic acid
Pharmaceutical Preparations

Keywords

  • Contrast media
  • Gadobenate dimeglumine
  • Gd-BOPTA
  • Iliac artery
  • Magnetic resonance angiography
  • Phase II clinical trial

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Wikström, J., Wasser, M. N., Pattynama, P. M. T., Bonomo, L., Hamm, B., Del Maschio, A., ... Ahlström, H. (2003). Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. Investigative Radiology, 38(8), 504-515. https://doi.org/10.1097/00004424-200308000-00005

Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. / Wikström, Johan; Wasser, Martin N.; Pattynama, Peter M T; Bonomo, Lorenzo; Hamm, Bernd; Del Maschio, Alessandro; Knopp, Michael V.; Marchal, Guy; Barentsz, Jelle O.; Oudkerk, Matthijs; Hentrich, Hans Rainer; Daprà, Massimo; Kirchin, Miles A.; Shen, Ningyan; Spinazzi, Alberto; Ahlström, Håkan.

In: Investigative Radiology, Vol. 38, No. 8, 01.08.2003, p. 504-515.

Research output: Contribution to journalArticle

Wikström, J, Wasser, MN, Pattynama, PMT, Bonomo, L, Hamm, B, Del Maschio, A, Knopp, MV, Marchal, G, Barentsz, JO, Oudkerk, M, Hentrich, HR, Daprà, M, Kirchin, MA, Shen, N, Spinazzi, A & Ahlström, H 2003, 'Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries', Investigative Radiology, vol. 38, no. 8, pp. 504-515. https://doi.org/10.1097/00004424-200308000-00005
Wikström, Johan ; Wasser, Martin N. ; Pattynama, Peter M T ; Bonomo, Lorenzo ; Hamm, Bernd ; Del Maschio, Alessandro ; Knopp, Michael V. ; Marchal, Guy ; Barentsz, Jelle O. ; Oudkerk, Matthijs ; Hentrich, Hans Rainer ; Daprà, Massimo ; Kirchin, Miles A. ; Shen, Ningyan ; Spinazzi, Alberto ; Ahlström, Håkan. / Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. In: Investigative Radiology. 2003 ; Vol. 38, No. 8. pp. 504-515.
@article{38b42e88e4ad4772bdae3b97ef2f8136,
title = "Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries",
abstract = "Rationale and Objectives: To evaluate 4 doses of gadobenate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (CE-MRA) of the pelvic arteries and to compare CE-MRA with unenhanced time-of-flight MRA (2D-TOF-MRA). Methods: A multicenter Phase II dose-finding study was performed in 136 patients with Gd-BOPTA doses of 0.025, 0.05, 0.1, and 0.2 mmuol/kg bodyweight. Evaluation of CE-MRA images and comparison with 2D-TOF-MRA images was performed onsite and by 2 blinded offsite reviewers in terms of subjective image quality, number of lesions detected, and confidence in lesion characterization. Results: Significant (P <0.05) improvements over unenhanced findings were observed for CE-MRA at all dose levels. For reviewer I and the onsite investigators, the overall image quality increased up to a dose of 0.1 mmol/kg and then plateaued. For reviewer 2, increased image quality was noted up to a dose of 0.2 mmol/kg. Significant (P <0.005) increases in diagnostic confidence on CE-MRA versus unenhanced MRA was observed for all dose groups by reviewer 1 and the onsite investigators and for the 0.1 and 0.2 mmol/kg dose groups by reviewer 2. No serious adverse events were recorded that were attributable to the study drug and no trends in laboratory parameters, vital signs, or electrocardiogram recordings were observed. Conclusions: Gadobenate dimeglumine-enhanced MRA is safe and significantly more effective than unenhanced 2D-TOF-MRA for imaging the pelvic arteries. A dose of 0.1 mmol/kg appears the most appropriate dose for subsequent Phase III clinical evaluation.",
keywords = "Contrast media, Gadobenate dimeglumine, Gd-BOPTA, Iliac artery, Magnetic resonance angiography, Phase II clinical trial",
author = "Johan Wikstr{\"o}m and Wasser, {Martin N.} and Pattynama, {Peter M T} and Lorenzo Bonomo and Bernd Hamm and {Del Maschio}, Alessandro and Knopp, {Michael V.} and Guy Marchal and Barentsz, {Jelle O.} and Matthijs Oudkerk and Hentrich, {Hans Rainer} and Massimo Dapr{\`a} and Kirchin, {Miles A.} and Ningyan Shen and Alberto Spinazzi and H{\aa}kan Ahlstr{\"o}m",
year = "2003",
month = "8",
day = "1",
doi = "10.1097/00004424-200308000-00005",
language = "English",
volume = "38",
pages = "504--515",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries

AU - Wikström, Johan

AU - Wasser, Martin N.

AU - Pattynama, Peter M T

AU - Bonomo, Lorenzo

AU - Hamm, Bernd

AU - Del Maschio, Alessandro

AU - Knopp, Michael V.

AU - Marchal, Guy

AU - Barentsz, Jelle O.

AU - Oudkerk, Matthijs

AU - Hentrich, Hans Rainer

AU - Daprà, Massimo

AU - Kirchin, Miles A.

AU - Shen, Ningyan

AU - Spinazzi, Alberto

AU - Ahlström, Håkan

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Rationale and Objectives: To evaluate 4 doses of gadobenate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (CE-MRA) of the pelvic arteries and to compare CE-MRA with unenhanced time-of-flight MRA (2D-TOF-MRA). Methods: A multicenter Phase II dose-finding study was performed in 136 patients with Gd-BOPTA doses of 0.025, 0.05, 0.1, and 0.2 mmuol/kg bodyweight. Evaluation of CE-MRA images and comparison with 2D-TOF-MRA images was performed onsite and by 2 blinded offsite reviewers in terms of subjective image quality, number of lesions detected, and confidence in lesion characterization. Results: Significant (P <0.05) improvements over unenhanced findings were observed for CE-MRA at all dose levels. For reviewer I and the onsite investigators, the overall image quality increased up to a dose of 0.1 mmol/kg and then plateaued. For reviewer 2, increased image quality was noted up to a dose of 0.2 mmol/kg. Significant (P <0.005) increases in diagnostic confidence on CE-MRA versus unenhanced MRA was observed for all dose groups by reviewer 1 and the onsite investigators and for the 0.1 and 0.2 mmol/kg dose groups by reviewer 2. No serious adverse events were recorded that were attributable to the study drug and no trends in laboratory parameters, vital signs, or electrocardiogram recordings were observed. Conclusions: Gadobenate dimeglumine-enhanced MRA is safe and significantly more effective than unenhanced 2D-TOF-MRA for imaging the pelvic arteries. A dose of 0.1 mmol/kg appears the most appropriate dose for subsequent Phase III clinical evaluation.

AB - Rationale and Objectives: To evaluate 4 doses of gadobenate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (CE-MRA) of the pelvic arteries and to compare CE-MRA with unenhanced time-of-flight MRA (2D-TOF-MRA). Methods: A multicenter Phase II dose-finding study was performed in 136 patients with Gd-BOPTA doses of 0.025, 0.05, 0.1, and 0.2 mmuol/kg bodyweight. Evaluation of CE-MRA images and comparison with 2D-TOF-MRA images was performed onsite and by 2 blinded offsite reviewers in terms of subjective image quality, number of lesions detected, and confidence in lesion characterization. Results: Significant (P <0.05) improvements over unenhanced findings were observed for CE-MRA at all dose levels. For reviewer I and the onsite investigators, the overall image quality increased up to a dose of 0.1 mmol/kg and then plateaued. For reviewer 2, increased image quality was noted up to a dose of 0.2 mmol/kg. Significant (P <0.005) increases in diagnostic confidence on CE-MRA versus unenhanced MRA was observed for all dose groups by reviewer 1 and the onsite investigators and for the 0.1 and 0.2 mmol/kg dose groups by reviewer 2. No serious adverse events were recorded that were attributable to the study drug and no trends in laboratory parameters, vital signs, or electrocardiogram recordings were observed. Conclusions: Gadobenate dimeglumine-enhanced MRA is safe and significantly more effective than unenhanced 2D-TOF-MRA for imaging the pelvic arteries. A dose of 0.1 mmol/kg appears the most appropriate dose for subsequent Phase III clinical evaluation.

KW - Contrast media

KW - Gadobenate dimeglumine

KW - Gd-BOPTA

KW - Iliac artery

KW - Magnetic resonance angiography

KW - Phase II clinical trial

UR - http://www.scopus.com/inward/record.url?scp=10744225127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744225127&partnerID=8YFLogxK

U2 - 10.1097/00004424-200308000-00005

DO - 10.1097/00004424-200308000-00005

M3 - Article

C2 - 12874517

AN - SCOPUS:10744225127

VL - 38

SP - 504

EP - 515

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 8

ER -